GLP-1

Type: Keyphrase
Name: GLP-1
First reported 9 hours ago - Updated 9 hours ago - 1 reports

Advantages of standardizing diabetes treatments

Ratings require JavaScript to be enabled.Medical treatment guidelines are suggestions that international organizations such as the American Diabetes Association, the European Society for the Study of Diabetes and the American Association of Clinical Endocrinologists, ... [Published Medical News Today - 9 hours ago]
First reported 16 hours ago - Updated 16 hours ago - 1 reports

In people with diabetes, consuming whey protein before meals could help improve blood glucose control

Ratings require JavaScript to be enabled.New research published in Diabetologia (the journal of the European Association for the Study of Diabetes) suggests that consuming whey protein before a regular breakfast reduces the blood sugar spikes seen after ... [Published Medical News Today - 16 hours ago]
First reported 21 hours ago - Updated 20 hours ago - 2 reports

Sanofi Teams Up With BST Japan To Develop GLP-1 Receptor Agonist Patch

Article # 28140708013Posted: Jul. 9, 2014 3:35 AM GMTExecutive SummarySanofi has announced a partnership with BioSerenTach , based in Kyoto city, regarding the development of a patch-type formulation of the GLP1 receptor agonist Lyxumia on June 26. ... [Published Health News Daily - 20 hours ago]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Study finds whey protein eases blood glucose management

New research has linked whey protein with better management of in people with , potentially opening the way for new management tactics.Whey protein is often used by dedicated gym goers and athletes, as it can boost overall fitness and stimulate muscle ... [Published Diabetes.co.uk - Jul 08 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Advantages of standardizing diabetes treatments

Medical treatment guidelines are suggestions that international organizations such as the American Diabetes Association, the European Society for the Study of Diabetes and the American Association of Clinical Endocrinologists, used to set the tone in ... [Published Medical Xpress - Jul 08 2014]
First reported Jul 06 2014 - Updated Jul 06 2014 - 1 reports

Benefits of two drugs in treating type 1 diabetes compared

The results of The Sanford Project's first clinical trial are published in the July edition of The Lancet Diabetes & Endocrinology , revealing the outcome of a two-year study exploring the benefits of two drugs in treating type 1 diabetes.The study is ... [Published Science Daily - Jul 06 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

The Sanford Project Publishes Results From Clinical Trial

Outcome of two-year study appears in national journal Contact InformationAvailable for logged-in reporters onlyCitationsThe Lancet Diabetes & Endocrinology, July 2014SIOUX FALLS, S.D. – The results of The Sanford Project’s first clinical trial are published ... [Published Newswise - Jul 03 2014]
First reported Jun 26 2014 - Updated Jun 27 2014 - 2 reports

Novo Nordisk's Diabetes Pill Shows Promise

By PLM Investments :Novo Nordisk ( NVO ) is generally recognized as one of the world's leaders in diabetes drug development and sales with over $2B in R&D spending in 2013, and 27% market share in diabetes care-higher than any other company. It continues ... [Published BioPortfolio - Jun 27 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 2 reports

Novo Nordisk exec: We'll double sales within 10 years

This has not been a great year for Denmark's Novo Nordisk ($NVO) so far--the diabetes drugmaker failed to post double-digit sales growth in first quarter for the first time in four years. But the company believes its 2014 performance is just a temporary ... [Published FiercePharma - Jun 25 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 2 reports

"Diabetes Is Primary": Primary Care Providers Are the Foundation of Diabetes Care

Saturday started early: a number of people were up at the crack of dawn preparing for the “Diabetes Is Primary” session that is a parallel program to the ADA Scientific Sessions. The fact that such a session is held is a significant recognition by the ... [Published Consultant Live - Jun 17 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 3 reports

Dulaglutide Superior to Insulin Glargine in Phase III Trials

Treatment reduces hemoglobin with lower risk of hypoglycemiaTwo pivotal phase III studies have shown that treatment with once-weekly dulaglutide (Eli Lilly) resulted in superior reductions in hemoglobin A 1c (HbA 1c ) from baseline compared with insulin ... [Published PT Community - Jun 17 2014]
First reported Jun 16 2014 - Updated Jun 17 2014 - 2 reports

Global type 2 diabetes pharmaceutical market totalled US$28.1Bn in 2012

- PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update - a new market research report on companiesandmarkets.comSales for Type 2 Diabetes by Region 2012â2022. This report focuses on type 2 diabetes pharmaceuticals ... [Published PR inside - Jun 17 2014]

Quotes

"If a patient has hypertension , obesity , overweight, cardiovascular damage, there is greater difficulty in achieving adequate treatment and is therefore more difficult to take it to the goals of excellence" said the specialist in endocrinology and nutrition
The authors conclude: "In summary, consumption of whey protein shortly before a high-glycaemic-index breakfast increased the early and late post-meal insulin secretion, improved GLP-1 responses and reduced post-meal blood sugar levels in type 2 diabetic patients. Whey protein may therefore represent a novel approach for enhancing glucose-lowering strategies in type 2 diabetes." They add that such treatment would be cheap and easy to administer, with patients able to use any brand of whey protein concentrate which has no added...
Original Article: NEXT ARTICLE More From BioPortfolio on "Sanofi Teams Up With BST Japan To Develop GLP-1 Receptor Agonist Patch"
Professor Daniela Jakubowicz who worked on the research at Tel Aviv University, said: "Consumption of whey protein shortly before breakfast increased the early and late post-meal insulin secretion, improved GLP-1 responses and reduced post-meal ." Treatment involving whey protein would be cheap and easy to administer, according to Professor Jakubowicz and the research has been cautiously welcomed...

More Content

All (200) | News (168) | Reports (0) | Blogs (26) | Audio/Video (0) | Fact Sheets (1) | Press Releases (4)
sort by: Date | Relevance
Advantages of standardizing diabetes treatments [Published Medical News Today - 9 hours ago]
Wednesday’s Top Biotech Stories: Celgene, AbbVi... [Published Motley Fool - 13 hours ago]
In people with diabetes, consuming whey protein... [Published Medical News Today - 16 hours ago]
Sanofi Teams Up With BST Japan To Develop GLP-1... [Published Health News Daily - 20 hours ago]
Sanofi Teams Up With BST Japan To Develop GLP-1... [Published BioPortfolio - 21 hours ago]
Sanofi's Basal Insulin Candidate Under FDA Review [Published Yahoo! Finance - Jul 08 2014]
Study finds whey protein eases blood glucose ma... [Published Diabetes.co.uk - Jul 08 2014]
Survey: Insulin Degludec/Liraglutide Set to Bec... [Published P&T Community - Jul 08 2014]
How Safe Are Antidiabetic Drugs? [Published General Medicine eJournal - Jul 08 2014]
Whey helps diabetics control blood sugar [Published Yahoo! Malaysia - Jul 08 2014]
Advantages of standardizing diabetes treatments [Published Medical Xpress - Jul 08 2014]
Diabetics Who Add Whey To Their Meals May Manag... [Published Medical Daily - Jul 07 2014]
Study suggests consuming whey protein before me... [Published Medical Xpress - Jul 07 2014]
Piramal’s NCE research shares preclinical effic... [Published Express Pharma - Jul 07 2014]
Novo Nordisk's Insulin Degludec/Liraglutide Is ... [Published TheStreet.com - Jul 07 2014]
Novo Nordisk's Insulin Degludec/Liraglutide is ... [Published TickerTech.com - Jul 07 2014]
Benefits of two drugs in treating type 1 diabet... [Published Science Daily - Jul 06 2014]
The Sanford Project Publishes Results From Clin... [Published Newswise - Jul 03 2014]
Novel Gut-Based Pharmacology of Metformin in Pa... [Published Plosone.org - Jul 02 2014]
Should AstraZeneca Buy MannKind? [Published Motley Fool - Jul 01 2014]
Conflicting Data on Sitagliptin and Heart Failu... [Published American Journal of Public Health - Jul 01 2014]
Advances for Type 2 Diabetes at The American Di... [Published diaTribe - Jul 01 2014]
Glycosylated GLP-1 peptide [Published Free Patents Online - Jul 01 2014]
IV noninva International Symposium (part 2) [Published Bariatric News - Jun 30 2014]
Isis announces encouraging results from Phase I... [Published Individual.com - Jun 30 2014]
Lexicon Pharmaceuticals announces encouraging d... [Published Individual.com - Jun 30 2014]
FLAMEL TECHNOLOGIES : Reveals Positive Preclini... [Published 4 Traders - Jun 30 2014]
ADA: Is Dulaglutide a Good Alternative to Metfo... [Published Diabetes in Control - Jun 28 2014]
Role of Endogenous GLP-1 and GIP in Beta Cell C... [Published Plosone.org - Jun 27 2014]
Access to pioneering research in Bordeaux France [Published TrustNet - Jun 27 2014]
1 2 3 4 5 6 7
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Flamel Technologies Announces Positive Preclini... [Published Marketwire - Breaking News Releases - Jun 25 2014]
LYON, FRANCE--(Marketwired - Jun 25, 2014) - Flamel Technologies (NASDAQ: FLML) today announced that its once weekly formulation of exenatide, based on its Medusa drug delivery platform, has been successfully tested in minipigs. Exenatide is a glucagon-like ...
ADA: Weekly GLP-1 Agonist Matches Daily Victoza... [Published MedPageToday.com - medical news plus CME for ph ... - Jun 17 2014]
SAN FRANCISCO (MedPage Today) -- The investigational weekly GLP-1 agonist dulaglutide improved glycemic control in type 2 diabetes comparably to daily liraglutide (Victoza) but with less weight loss, researchers reported here. ...
Intarcia Presents Interim Phase 3 Data at ADA S... [Published PR Newswire: General Business - Jun 15 2014]
BOSTON, June 15, 2014 /PRNewswire/ --  Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74th Scientific Sessions of the American Diabetes Association (ADA) held in San Francisco that contained the first 6-month ...
Phase 3a Data Showed Liraglutide 3 mg Demonstra... [Published PR Newswire: Health - Jun 14 2014]
SAN FRANCISCO, June 14, 2014 /PRNewswire/ --Today, primary results from SCALE™ Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue for chronic weight management, were presented ...
Top medicine articles for May 2014 [Published Clinical Cases and Images: CasesBlog - May 28 2014]
A collection of some interesting medical articles published recently:Epinephrine May Be of No Survival Benefit in Cardiac Arrest - NEJM Journal Watch http://buff.ly/1ntp0do Albiglutide (Tanzeum), glucagon-like peptide-1 (GLP-1) receptor agonist, approved ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Zealand provides summary of new clinical data a... [Published GlobeNewswire: Advertising News - Jun 17 2014]
Zealand presented new data on two novel peptide... [Published GlobeNewswire: Acquisitions News - Jun 17 2014]
Presentation of several Zealand peptide therape... [Published GlobeNewswire: Advertising News - Jun 10 2014]
Zealand and Boehringer Ingelheim to change deve... [Published GlobeNewswire: Acquisitions News - Jan 20 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.